-
2024.02.26SanegeneBio siRNA drug targeting C3 has been approved for Phase I clinical trial in New ZealandMore
-
2023.12.27SanegeneBio and Innovent Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of HypertensionMore
-
2023.12.01SanegeneBio Raised nearly $100 Million in Series A+ Financing Led by Tencent Investment and Yuanbio Venture Capital, to Advance Development of RNAi TherapeuticsMore
-
2023.11.09SanegeneBio and Huadong Medicine Collaborate to Develop Novel siRNA Drugs for the Treatment of Chronic Metabolic DiseasesMore
-
2023.10.07SanegeneBio first RNAi drug was approved for clinical trial in ChinaMore
-
2023.07.12Pharma DJ: SanegeneBio: an innovator for RNAi drugsPharmaDJ interviewed SanegeneBio's CEOMore
-
2023.05.31Sanegene Announces Dosing of the First Subject in Phase I Trial of SGB-3403 Targeting PCSK9 for the Treatment of HypercholesterolemiaMore
